NVS logo

Novartis AG

NVS
Healthcare|Drug Manufacturers - General|CH
$162.55
+0.62 (+0.38%)
DCF Value
$269.57
Graham Number
$48.20
Cash / Share
$4.75

About

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is heavily focused on innovative prescription medicines, especially oncology, immunology, neuroscience, and cardiovascular diseases, supplemented by established older brands and a wide range of specialized therapies. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Stock Price

+28.4%(1Y)
1M
+13.6%
3M
+4.0%
6M
+11.3%
YTD
+17.9%
1Y
+27.8%
3Y
+72.2%
5Y
+106.4%

Pipeline Summary

527 total trials
101
Phase 1
182
Phase 2
136
Phase 3
64
Phase 4
Active: 27Completed: 371Unknown: 8Terminated: 64Recruiting: 31Not Yet Recruiting: 4Withdrawn: 19No Longer Available: 3

Active Trials (58)

Development of Novel Clinical Endpoints in Intermediate AMD
NCT03349801Age Related Macular Degeneration (AMD)
Active
Enrollment: 718 participants
A Post-treatment Program to Identify and Manage Complications Related to Oncology or Hematology Treatments in Cancer Survivors.
NCT04671693Late Effects
N/AActive
Enrollment: 500 participants
Real World Study Using Comprehensive Genomic Data on the Next Treatment Decision Making in Metastatic Breast Cancer
NCT04497285Metastatic Breast Cancer
Active
Enrollment: 600 participants
DreaMS - Validation Study 1
NCT05009160Multiple Sclerosis
Active
Enrollment: 300 participants
MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)
NCT04111978Ovarian Neoplasm Epithelial
Phase 3Recruiting
Enrollment: 540 participants

BioScore

5.4/10
Watchlist

Key Facts

Market Cap$307.00B
Employees75,267
CEOVasant Narasimhan
IPO DateNov 7, 1996
Beta0.41
52-Week Range$123.24 – $170.46
Avg Volume1,973,430
ExchangeNYSE

Ownership

Float96.9%
Shares Outstanding1888.6M

Peers

ABBVAbbVie Inc.
$514.78B
AZNAstraZeneca PLC
$289.14B
BMYBristol-Myers Squibb Company
$127.02B
GILDGilead Sciences, Inc.
$207.00B
GSKGSK plc
$102.02B
JNJJohnson & Johnson
$664.95B
MRKMerck & Co., Inc.
$361.96B
NVONovo Nordisk A/S
$177.74B
Data last updated: Nov 9, 2026, 04:25 AM